Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure

Inclusion Criteria: * Provision of signed informed consent prior to any study specific procedures * Male or female, aged ≥18 years * Established documented diagnosis of symptomatic HFrEF (NYHA functional class II-IV), which has been present for at least 2 months * LVEF≤40% * Elevated NT-proBNP levels * Patients should receive background standard of care for HFrEF and be treated according to locally recognized guidelines * eGFR ≥30 mL/min/1.73 m\^2 (CKD-EPI formula) at enrolment (visit 1) Exclusion Criteria: * Receiving therapy with an SGLT2 inhibitor within 8 weeks prior to enrolment or previous intolerance of an SGLT2 inhibitor * Type 1 diabetes mellitus * Symptomatic hypotension or systolic BP \<95 mmHg at 2 out of 3 measurements either at visit 1 or visit 2 * Current acute decompensated HF or hospitalization due to decompensated HF \<4 weeks prior to enrolment * MI, unstable angina, stroke or transient ischemic attack within 12 weeks prior to enrolment * Coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting) or valvular repair/replacement within 12 weeks prior to enrolment or planned to undergo any of these operations after randomization * Implantation of a CRT within 12 weeks prior to enrolment or intent to implant a CRT device * Previous cardiac transplantation or implantation of a ventricular assistance device or similar device, or implantation expected after randomization * HF due to restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, hypertrophic (obstructive) cardiomyopathy or uncorrected primary valvular disease * Symptomatic bradycardia or second or third degree heart block without a pacemaker * Severe (eGFR \<30 mL/min/1.73 m\^2 by CKD-EPI), unstable or rapidly progressing renal disease at the time of randomization